期刊文献+

疫苗生产场地变更质量可比性研究的总体思考 被引量:10

Comments and recommendations on comparability of vaccines related to manufacturing site changes: quality issues
原文传递
导出
摘要 由于疫苗生产产业化和法规升级等因素的要求,疫苗生产场地需要进行变更。可比性研究有利于控制场地变更对疫苗安全性、有效性带来的风险,是变更成功的桥梁。本文结合国内外技术指导原则的解读和疫苗产品的特点,对我国疫苗场地变更的质量可比性研究作一综述。 Increase in product yield and complementation of the requirement of national regulatory agency are driving to site changes of vaccines. Comparability exercise is the bridge to a successful change, which would ascertain that introduction of the manufacturing site change did not alter the safety and efficacy profile of the product, This paper introduced the core element of the international guideline, and put forwards considerations on designing and fulfilling comparability study regards to vaccine quality assessment.
出处 《中国生物制品学杂志》 CAS CSCD 2013年第2期289-291,296,共4页 Chinese Journal of Biologicals
关键词 疫苗 场地变更 可比性 Vaccine Manufacturing site change Comparability
  • 相关文献

参考文献7

  • 1沈心亮,蒋韬.中国疫苗应用现状与发展趋势[J].微生物学免疫学进展,2003,31(4):60-66. 被引量:4
  • 2European Commission. Communication from the Commission - Guideline on the details of the various categories of variations to the terms of marketing authorizations for medicinal products for human use and veterinary medicinal products [J]. Official J Eur Union, 2010, 22 ( 1 ): C17 / 1-C17 / 44.
  • 3ICH Q5E. Comparability of biotechnological/biological products subject to changes in their manufacturing process (CPMP/ICH/ 5721/03) [S]. 2005.
  • 4FDA. FDA guidance concerning demonstration of comparability of human biological products, including therapeutic biotech- nology-defived products [S]. 1987.
  • 5EMA. Guideline on comparability of bioteehnology-derived medicinal products after a change in the manufacturing process: quality issues (CPMP/BWP/3207/00 Rev.1 ) [S]. 2003.
  • 6EMA. Guideline on comparability of biotechnology-derived medieinal products after a change in the manufacturing process: non-elinieal and clinical issues(EMEA / CHMP / BMWP / 10695 /2006) [S]. 2007.
  • 7PDA. Process validation of protein manufacturing [J]. PDA J Pharmac Sci Technol, 2005, 59 (S4): 1-28.

二级参考文献10

  • 1Hinman A R. Global progress in infections disease control[J].Vaccine 1998, 16:1116-1121.
  • 2WolffJ A, Malone R W, Williams P, et al. Direct gene transfer into mouse muscle in vivo[J]. Science 1990, 247:1465-1468.
  • 3Plotkin S L, Plotkin S A.A short history of vaccination[ M]. In:Plotin S A,Plotldn S A, Orenstein W A, ed. Vaccines. 3rd rev ed. Philadelphia:saunders 1999, 1-8.
  • 4Van der Marel P, Hazendank T G, Heneke M A C,et al. Induction of neutralizing antibodies by poliovirus eapsid polypeptides YP1, VP2 and VP3[J]. Vaccine 1983, 1:17-22.
  • 5Tulchinsky T H, l-landsher R, Melnick J L,et al. Immune status to various strains of wild poliovims among children in Gaza immunized with live attenuated oral vaccine alone compaared with combination of live and inactivated vaccines[J]. J Viral Dis 1993, 1:1-9.
  • 6Cohen S, Mendelson I, Altboum Z, et al. Attenuated nontoinogenic and nonencasulated recombinant Bacillus anthracis spore vaccines protect against Athrax [J]. Infect Immun 2000, 68:4549-4558.
  • 7Zhu X, Venkataprasacl N, ]vanyi J, et al. Vaccination with recombinant vaccinia viruses protects mice against Mycobacterium tuberculosis Infection[J]. Immunol 1997, 92:6-9.
  • 8Lowrie D B,Silva C L, Colston M J, et al. Therapy of tuberculosis in mice by DNA vaccination[J]. Nature 1999, 400:269-271.
  • 9Viret J F, Favre D, WegmuUer B, et al. Mucosal and systemic immune responses in humans after primary and booster immunization with orally administered invasive and noninvasive llve attenuated bacteria[J]. Infect Immun 1999, 180:2089-2090.
  • 10Robinson A, Irons L I, Ashworth L A E. Pertussis vaccine:present status and future prospects[J]. Vaccine 1985, 3:11-22.

共引文献3

同被引文献44

引证文献10

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部